Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis

Internal Medicine

Volumn 55, Issue 5, 2016, Pages 443-448

  Bando, Masashi ^a   Yamauchi, Hiroyoshi ^a   Ogura, Takashi ^b   Taniguchi, Hiroyuki ^c   Watanabe, Kentaro ^d   Azuma, Arata ^e   Homma, Sakae ^f   Sugiyama, Yukihiko ^a   Chida, K ^g   Keicho, N ^h   Nakanishi, Y ⁱ   Inase, N ^j   Nishimura, M ^k   Inoue, Y ^l   Mukae, H ^m   Yokoyama, A ⁿ   Taguchi, Y ^o   Takizawa, H ^p   Mishima, M ^q   Nishioka, Y ^r   Ishii, Y ^s   Munakata, M ^t   Kohno, N ^u   Kishi, Hiroshima K ^v   more..

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^c TOSEI GENERAL HOSPITAL   (Japan)

^d FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NIPPON MEDICAL SCHOOL   (Japan)

^f TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^g HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^k HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^l NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^m UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

ⁿ KOCHI MEDICAL SCHOOL HOSPITAL   (Japan)

^o TENRI HOSPITAL   (Japan)

^p TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q KYOTO UNIVERSITY   (Japan)

^r UNIVERSITY OF TOKUSHIMA   (Japan)

^s DOKKYO MEDICAL UNIVERSITY   (Japan)

^t FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^u HIROSHIMA UNIVERSITY   (Japan)

^v TORANOMON HOSPITAL   (Japan)

more..

Author keywords

Idiopathic pulmonary fibrosis; Long term use; Pirfenidone

Indexed keywords

PIRFENIDONE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

AGED; ARTICLE; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECTS; EPIDEMIOLOGY; IDIOPATHIC PULMONARY FIBROSIS; JAPAN; MULTICENTER STUDY; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; VITAL CAPACITY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; JAPAN; MALE; PYRIDONES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84959263791     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.55.5272     Document Type: Article

References (13)

1. Raghu G, Collard HR, Egan JJ, et al; on behalf of the ATS/ERS/ JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824, 2011.
2. Diagnosis and treatment guidance of idiopathic interstitial pneumonia. 2nd ed. The Japanese Respiratory Society Diagnosis and Treatment Guidelines Construction Committee, Ed. Nankodo, Tokyo, 2011(in Japanese).
3. Azuma A. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 6: 107-114, 2012.
4. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590: 400-408, 2008.
5. Taniguchi H, Ebina M, Kondoh Y, et al; the Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35: 821-829, 2010.
6. King TE Jr, Bradford WZ, Castro-Bernardini S, et al; ASCEND study group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370: 2083-2092, 2014.
7. Noble PW, Albera C, Bradford WZ, et al; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 377: 1760-1769, 2011.
8. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183: 431-440, 2011.
9. Okuda R, Hagiwara E, Baba T, Kitamura H, Kato T, Ogura T. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 107: 1431-1437, 2013.
10. Schmidt SL, Tayob N, Han MK, et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 145: 579-585, 2014.
11. Taniguchi H, Kondoh Y, Ebina M, et al; Pirfenidone Clinical Study Group in Japan. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 12: 93, 2011.
12. Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: Real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 88: 199-207, 2014.
13. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 19: 740-747, 2014.